Uptrend on the daily chart: above its 50- and 200-day averages · 50-day below the 200-day · SuperTrend up since Sep 29 · above the Ichimoku cloud · RSI 55 · MACD above its signal
None of the 29 investors followed here reported a position in RVV.CN in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a RVV.CN trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Jul 9, 2024 | Lindzon (Andrew Stuart)Director of Issuer | Acquisition or disposition in the public market at price 0.01 per share. | 333K | $3.66K |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 50.0 | -33.3 | 250.0 | 0.0 | 0.0 | -14.3 | -16.7 | 0.0 | 0.0 | 20.0 | +200.0% | ||
| 2025 | 0.0 | 0.0 | 50.0 | 100.0 | 0.0 | -33.3 | 0.0 | 0.0 | -25.0 | 0.0 | -33.3 | 0.0 | 0.0% |
| 2024 | -16.7 | 0.0 | 0.0 | 0.0 | 0.0 | -60.0 | 0.0 | 50.0 | -33.3 | -50.0 | 100.0 | 0.0 | −66.7% |
| 2023 | 21.7 | -7.1 | -57.7 | 45.5 | -37.5 | -10.0 | -44.4 | 60.0 | 0.0 | -25.0 | 0.0 | 0.0 | −73.9% |
| 2022 | -17.6 | -10.7 | -26.0 | 73.0 | 39.1 | 3.4 | -8.7 | -14.3 | -34.7 | -2.1 | -23.9 | -34.3 | −66.2% |
| 2021 | -9.7 | -8.9 | -4.9 | -1.0 | -3.1 | 26.9 | -16.9 | -17.3 | 11.1 | 5.6 | 13.7 | -37.0 | −45.2% |
| 2020 | -16.7 | 10.0 | 90.9 | 47.6 | 87.1 | 0.0 | 36.2 | -24.1 | -10.0 | -25.9 | 42.5 | 117.5 | +933.3% |
| 2019 | 0.0 | 16.7 | 4.8 | 27.3 | -25.0 | -9.5 | -21.1 | -33.3 | 10.0 | -27.3 | -12.5 | 71.4 | −33.3% |
| 2018 | -21.7 | -30.8 | -6.7 | 2.4 | -4.7 | -2.4 | -22.5 | 41.9 | -18.2 | -19.4 | -17.2 | -25.0 | −78.3% |
| 2017 | 8.7 | 152.0 | -30.2 | 2.3 | -11.1 | 5.0 | -11.9 | -8.1 | 2.9 | -2.9 | 91.2 | 27.7 | +260.9% |
| 2016 | -17.7 | -31.4 | -60.0 | -21.4 | 21.5 | -9.5 | 21.1 | 13.0 | 76.9 | -32.6 | -22.6 | -4.2 | −76.4% |
| 2015 | -8.3 | 1.8 | 51.8 | -11.8 | 0.0 | -22.7 | -19.0 | 6.4 | 30.0 | 15.4 | -6.7 | -11.4 | +3.3% |
| 2014 | 65.0 | -18.2 | 1.9 | 9.1 | -25.0 | 6.7 | 20.8 | 22.4 | 5.6 | -32.0 | 54.9 | -24.1 | +50.0% |
| 2013 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0% |
No analyst coverage for this instrument.
Revive Therapeutics Ltd., a life sciences company, focuses on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders. It develops Bucillamine, a disease-modifying anti-rheumatic drug, for the treatment of infectious diseases, including influenza and COVID-19, as well as to treat pandemic influenza, emerging infectious diseases, and medical countermeasure incidents and attacks. The company also develops Psilocybin, which is in Phase 1 clinical study for treating methamphetamine use disorder; and Psilocin for the treatment of depression, anxiety, bi-polar disorder, bulimia and anorexia nervosa, and other diseases. Revive Therapeutics Ltd. is based in Toronto, Canada.
No recent headlines.